Gossamer Bio Inc. (GOSS)
| Bid | 1.2 |
| Market Cap | 276.46M |
| Revenue (ttm) | 112.23M |
| Net Income (ttm) | -71.73M |
| EPS (ttm) | -0.25 |
| PE Ratio (ttm) | -4.88 |
| Forward PE | -1.3 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 1,128,632 |
| Avg. Volume (20D) | 1,656,025 |
| Open | 1.12 |
| Previous Close | 1.19 |
| Day's Range | 1.10 - 1.22 |
| 52-Week Range | 0.50 - 1.60 |
| Beta | 1.81 |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...
Analyst Forecast
According to 5 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 637.70% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILDGossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far prod...
